A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor: Hoffmann-La Roche
Listed as NCT02600897, this PHASE1/PHASE2 trial focuses on Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 40 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
40 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Mar 2022 — Jan 2024 [monthly]
Completed PHASE1
▶ Show 35 earlier versions
-
Feb 2022 — Mar 2022 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Mar 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Oct 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE1
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE1
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE1
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE1
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Apr 2018 [monthly]
Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .